Heartflow Inc Stock News

First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs.

Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions

MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and organic2 basis, all compared to the prior year period.

FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific p...

SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by ...

Heartflow stock broke out Friday, helped by an "outsized" guidance raise and second-quarter beat.

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026.